Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE44.8400
- TODAY'S CHANGE (%)-0.4900 (-1.0810%)
- Bid / Lots44.7700/ 4
- Ask / Lots44.9400/ 4
- Open / Previous Close45.1200 / 45.3300
- Day Range
- 52 Week Range
- Volume142,064
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 6101 | 45.2 |
| 09:34 ET | 600 | 44.7401 |
| 09:36 ET | 200 | 44.945 |
| 09:38 ET | 600 | 44.93 |
| 09:39 ET | 100 | 44.99 |
| 09:41 ET | 600 | 44.86 |
| 09:43 ET | 3500 | 45.0675 |
| 09:45 ET | 9700 | 45 |
| 09:48 ET | 11704 | 44.975 |
| 09:50 ET | 2100 | 45.16 |
| 09:52 ET | 2458 | 45.12 |
| 09:54 ET | 850 | 45.41 |
| 09:56 ET | 400 | 45.63 |
| 09:57 ET | 2012 | 45.5 |
| 09:59 ET | 2400 | 45.54 |
| 10:01 ET | 500 | 45.57 |
| 10:03 ET | 100 | 45.565 |
| 10:06 ET | 1000 | 45.3 |
| 10:10 ET | 800 | 45.185 |
| 10:12 ET | 1500 | 45.165 |
| 10:14 ET | 1011 | 45.02 |
| 10:15 ET | 100 | 44.96 |
| 10:17 ET | 400 | 45.02 |
| 10:19 ET | 200 | 44.975 |
| 10:26 ET | 100 | 44.855 |
| 10:28 ET | 200 | 44.855 |
| 10:30 ET | 300 | 44.89 |
| 10:32 ET | 400 | 44.81 |
| 10:37 ET | 500 | 44.8 |
| 10:39 ET | 200 | 44.79 |
| 10:42 ET | 800 | 44.67 |
| 10:44 ET | 200 | 44.535 |
| 10:46 ET | 600 | 44.6 |
| 10:48 ET | 1500 | 44.78 |
| 10:50 ET | 600 | 44.775 |
| 10:51 ET | 1569 | 44.77 |
| 10:53 ET | 100 | 44.9 |
| 10:57 ET | 100 | 44.88 |
| 11:00 ET | 800 | 44.88 |
| 11:02 ET | 500 | 44.84 |
| 11:04 ET | 25500 | 44.81 |
| 11:06 ET | 278 | 44.7968 |
| 11:08 ET | 823 | 44.72 |
| 11:09 ET | 1222 | 44.625 |
| 11:11 ET | 3158 | 44.53 |
| 11:13 ET | 400 | 44.5 |
| 11:15 ET | 100 | 44.485 |
| 11:18 ET | 500 | 44.54 |
| 11:20 ET | 300 | 44.54 |
| 11:22 ET | 2900 | 44.515 |
| 11:24 ET | 300 | 44.53 |
| 11:26 ET | 400 | 44.58 |
| 11:29 ET | 748 | 44.572 |
| 11:31 ET | 300 | 44.54 |
| 11:36 ET | 200 | 44.49 |
| 11:38 ET | 100 | 44.445 |
| 11:40 ET | 500 | 44.445 |
| 11:42 ET | 235 | 44.3801 |
| 11:44 ET | 250 | 44.56 |
| 11:49 ET | 100 | 44.57 |
| 11:51 ET | 900 | 44.525 |
| 11:54 ET | 700 | 44.425 |
| 11:56 ET | 1450 | 44.45 |
| 11:58 ET | 2383 | 44.5301 |
| 12:00 ET | 100 | 44.635 |
| 12:02 ET | 200 | 44.705 |
| 12:03 ET | 577 | 44.84 |
Jun 10, 2024
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 6:35PM ET on Monday Jun 10, 2024 by Dow Jones
6:35PM ET on Monday Jun 10, 2024 by Dow Jones
Jun 4, 2024
DJ Crinetics Pharmaceuticals Price Target Maintained With a $80.00/Share by JMP Securities, from 8:29AM ET on Tuesday Jun 04, 2024 by Dow Jones
8:29AM ET on Tuesday Jun 04, 2024 by Dow JonesDJ Crinetics Pharmaceuticals Is Maintained at Outperform by Oppenheimer, from 8:19AM ET on Tuesday Jun 04, 2024 by Dow Jones
8:19AM ET on Tuesday Jun 04, 2024 by Dow JonesDJ Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 7:37AM ET on Tuesday Jun 04, 2024 by Dow Jones
7:37AM ET on Tuesday Jun 04, 2024 by Dow Jones
Jun 3, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.6B | -11.9x | --- |
Immunovant Inc | 3.8B | -14.0x | --- |
Avidity Biosciences Inc | 3.8B | -13.4x | --- |
Dyne Therapeutics Inc | 3.3B | -8.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Merus NV | 3.8B | -20.7x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- President, Chief Executive Officer, Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.6B |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.68 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -11.9x |
Price/Sales (TTM) | 1,810.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
